A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades

AIDS Research and Human Retroviruses

Volumn 14, Issue 3, 1998, Pages 213-221

  Gorny, Miroslaw K ^a   Mascola, John R ^b   Israel, Zimra R ^a,c   VanCott, Thomas C ^d   Williams, Constance ^a   Balfe, Peter ^e   Hioe, Catarina ^a   Brodine, Stephanie ^f   Burda, Sherri ^a   Zolla Pazner, Susan ^a,g  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN MONOCLONAL ANTIBODY;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN DETECTION; ARTICLE; BINDING KINETICS; CROSS REACTION; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

EID: 0032502014     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.213     Document Type: Article

References (41)

1. Artenstein AW, Coppola J, Brown AE, et al.: Multiple introductions of HIV-1 subtype E into the western hemisphere. Lancet 1995;346:1197-1198.
2. Brodine SK, Mascola JR, Weiss PJ, et al.: Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995;346:1198-1199.
3. Irwin KL, Pau CP, Lupo D, et al.: Presence of HIV-1 subtype A infection in a New York community with high HIV prevalence: A sentinel site for monitoring HIV genetic diversity in North America. J Infect Dis 1997;176:1629-1633.
4. Zolla-Pazner S, O'Leary J, Burda S, Gorny MK, Kim M, Mascola J, and McCutchan F: Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol 1995;69:3807-3815.
5. Nyambi PN, Nkengasong J, Lewi P, et al.: Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996;70:6235-6243.
6. Moore JP, Cao Y, Leu J, Qin L, Korber B, and Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70:427-444.
7. Weber J, Fenyö E-M, Beddows S, Kaleebu P, Bjorndal A, and the WHO Network for HIV Isolation and Characterization: Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtype. J Virol 1996;70:7827-7832.
8. Moore JP, Trkola A, Korber B, et al.: A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 1995;69:122-130.
9. Mascola JR, Louwagie J, McCutchan FE, et al.: Two antigenically distinct subtypes of HIV-1: Viral genotype predicts neutralization immunotype. J Infect Dis 1994;169:48-54.
10. Mascola JR, Louder MK, Surman SR, et al.: Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996;12:1319-1328.
11. Moore JP, McCutchan FE, Poon S, Mascola J, Liu J, Cao Y, and Ho DD: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994;68:8350-8364.
12. Burke DS, Fowler AK, Redfield RR, Dilworth S, and Oster CN: Isolation of HIV-1 from the blood of seropositive adults; Patient stage of illness and sample inoculum size are major determinants of a positive culture. J AIDS 1990;3:1159-1167.
13. McCutchan FE, Artenstein AW, Sanders-Buell E, et al.: Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa. J Virol 1996;70:3331-3338.
14. McCutchan FE, Hegerich P, Brennan T, et al.: Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8: 1887-1895.
15. Ichimura H, Kliks SC, Visrutaratna S, Ou C, Kalish KL, and Levy JA: Biological, serological and genetic characterization of HIV-1 subtype E isolates from northern Thailand. AIDS Res Hum Retroviruses 1994;10:263-269.
16. Johnson VA and Byington RE: Infectivity assay (virus yield assay). In: Techniques in HIV Research (Aldovini A and Walker BD, eds.). Stockton Press, New York, 1990, pp. 71-76.
17. Delwart EL, Schpaer EG, McCutchan FE, Louwagie J, Grez M, Rübsamen-Waigmann H, and Mullins JI: Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 1993;262:1257-1261.
18. Nyambi PN, Nkengasong J, Peeters M, et al.: Reduced capacity of antibodies from patients infected with human immunodeficiency virus type-1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis 1995;172:1228-1237.
19. Gorny MK, Xu J-Y, Gianakakos V, et al.: Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 1991;88:3238-3242.
20. Gorny MK: Production of human monoclonal antibodies via fusion of Epstein-Barr virus-transformed lymphocytes with heteromyeloma. In: Cell Biology: A Laboratory Handbook (Celis JE, ed.). Academic Press, New York, 1994, pp. 276-281.
21. Teng NN, Lam KS, Riera FC, and Kaplan HS: Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production. Proc Natl Acad Sci USA 1983;80:7308-7312.
22. Gorny MK, Xu J, Karwowska S, Buchbinder A, Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993;150:635-643.
23. Karwowska S, Gorny MK, Culpepper S, Burda S, Laal S, Samanich K, and Zolla-Pazner S: The similarities and diversity among human monoclonal antibodies to the CD4-binding domain of HIV-1. In: Vaccines 93: Modern Approaches to Vaccine Including Prevention of AIDS (Brown F, Sinsberg HS, and Lerner R, eds.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1993, pp. 229-232.
24. Gorny MK, Gianakakos V, Sharpe S, and Zolla-Pazner S: Generation of human monoclonal antibodies to HIV. Proc Natl Acad Sci USA 1989;86:1624-1628.
25. McKeating JA, Zhang Y, Arnold C, Frederiksson R, Fenyö E, and Balfe P: Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type 1 show increased sensitivity to neutralization by human sera. Virology 1996;220:450-460.
26. Israel ZR, Gorny MK, Palmer C, McKeating JA, and Zolla-Pazner S: Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1 infected individuals. AIDS 1997;11:128-130.
27. VanCott TC, Bethkes FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield RR, and Birx DL: Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol 1994;153:449-459.
28. Zolla-Pazner S and Sharpe S: A resting cell assay for improved detection of antibody-mediated neutralization of HIV-1 primary isolates. AIDS Res Hum Retroviruses 1995;11:1449-1457.
29. Laal S, Burda S, Sharpe S, and Zolla-Pazner S: A rapid, automated microtiter assay for measuring neutralization for HIV-1. AIDS Res Hum Retroviruses 1993;9:781-785.
30. Mascola JR, Snyder SW, Weislow OS, et al.: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
31. Gorny MK, Conley AJ, Karwowska S, et al.: Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-7542.
32. Korber BTM, MacInnes K, Smith RF, and Myers G: Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994;68:6730-6744.
33. Barin F, Lahbabi Y, Buzelay L, et al.: Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: An approach for HIV type serological subtyping. AIDS Res Hum Retroviruses 1996;12:1279-1289.
34. Cheingsong-Popov R, Lister S, Callow D, Kaleebu P, Beddows S, Weber J, and the WHO Network for HIV Isolation and Characterization: Serotyping HIV type 1 by antibody binding to the V3 loop: Relationship to viral genotype. AIDS Res Hum Retroviruses 1994;10:1379-1386.
35. Gorny MK, VanCott TC, Israel ZR, et al.: Human monoclonal antibodies to the V3 loop of HIV-1 with ultra- and interclade cross-reactivity. J Immunol 1997;159:5114-5122.
36. Conley AJ, Gorny MK, Kessler JA II, et al.: Neutralization of primary HIV-1 virus isolates by the broadly-reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
37. Sawyer LW, Wrin MT, Crawford-Miksza L, et al.: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994;68:1342-1349.
38. Wrin T, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH: Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
39. Bastiani L, Laal S, Zolla-Pazner S, and Kim M: Host cell-dependent alterations in envelope components of HIV-1 virions. J Virol 1997;71:3444-3450.
40. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
41. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, and Golding H: Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996;274:602-605.